Trial finds type 2 diabetes drug liraglutide can affect heart rate variability

The type 2 diabetes drug liraglutide could affect heart variability in newly diagnosed people who are overweight and have heart problems, according to new research. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which helps control blood sugar levels and reduces post-meal hyperglycemia. The drug is marketed as Victoza and Saxenda.

Read more

Posted in Type II Drugs